Can better education ease statin side effect worries?
NCT ID NCT07094412
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study aims to develop and test educational content that explains statin side effects, including placebo and nocebo effects. Researchers will gather feedback from 30 adults with cardiovascular risk factors through surveys and interviews. The goal is to see if this content is feasible and acceptable to patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- educational content on statin side effects
- What this could lead to
- If successful, this could lead to better educational tools that help patients understand and manage statin side effects, potentially improving medication adherence.
- What could go wrong
- This is a small, early-stage pilot study with only 30 participants, so results may not apply to everyone. It focuses on education, not a new treatment, so it won't directly change medical outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Has at least one cardiovascular risk factor, including diabetes (DM), hypertension (HTN), hyperlipidemia (HLD), or a 10-year risk of atherosclerotic cardiovascular disease (ASCVD) of equal to or greater than 7.5% * Able to speak and read English Exclusion Criteria: * Established diagnosis of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease (CAD), peripheral arterial disease (PAD), or history of stroke * Unable to access and engage with web-based education content for any reason (either independently or with the help of a support person) * Is a healthcare professional at the college level or above, defined as a registered nurse, nurse practitioner, physician assistant, physician, dentist, or pharmacist * Has a graduate-level degree of any kind * Hospice or end-of-life
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Weill Cornell Medicine
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smoking and diet may shape cholesterol in mexican adults
- Triple-Drug cholesterol attack aims to strike within 72 hours of a heart attack
- New pill aims to lower 'Bad' cholesterol: first human test begins
- Vitamin B3 supplement put to the test against psoriasis inflammation
- Can cottonseed oil improve cholesterol? trial tests common cooking oil against similar blends
- Can big data unmask hidden clusters of cardiometabolic disease?